Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABCL vs RAPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABCL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

ABCL Overall Winner 6-Pillar Tally: ABCL 4 – 1 RAPT (1 Tie) Matrix Metrics: ABCL 6 – 4 RAPT

As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ABCL carries a Unified Composite Score of 63.3/100 (BUY) at $11.14 (27.6x Forward P/E, -1550.0% operating margin), whereas RAPT carries 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABCL vs RAPT
ABCL NASDAQ Head-to-Head Winner
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.14
-3.08% 1D
Market Cap $3.8B
TTM Revenue $66M
Forward P/E 27.6x
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
63.3 / 100 BUY
Tech 57.0 Fund 58.0 Flow 67.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 43.3 · SMA20: $12.04 · SMA50: $12.33
RAPT NASDAQ
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 2% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (27.1% over 20 days), RSI 80
RSI-14: 79.7 · SMA20: $57.82 · SMA50: $47.67

6-Pillar Scorecard Institutional Category Breakdown (ABCL 4 – 1 RAPT)

Columns: Metric · ABCL · RAPT
1. Valuation Multiples ABCL
Forward P/E 27.6x N/M
Trailing P/E 27.6x N/M
PEG Ratio N/M N/M
EV / Revenue 56.9x N/M
2. Growth & Scale ABCL
Revenue Growth (YoY) -76.3% -100.0%
Earnings Growth (YoY) +45.9% +0.0%
TTM Revenue (USD) $66M N/A
Market Cap $3.8B $1.7B
3. Profitability & Quality RAPT
Gross Margin N/A N/A
Operating Margin -1550.0% 0.0%
Net Profit Margin -248.8% 0.0%
Return on Equity (ROE) -17.3% -85.4%
4. Balance Sheet & Cash Flow ABCL
Cash Generation (TTM) -$33M N/A
Cash Flow Margin -49.6% N/A
Net Cash / Leverage $30M Net Cash $9.02 Book/Sh · -85.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABCL
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 80.8% (25th %ile) 0.8% (<1st %ile)
Put/Call OI Skew 0.23x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABCL (6) vs RAPT (4)
Institutional Metric ABCL RAPT Criterion Row Edge
Market Capitalization
Scale
$3.8B $1.7B Larger Scale ABCL
Trailing P/E Ratio
Valuation
27.6x N/M Lower Multiple ABCL
Forward P/E Ratio
Valuation
27.6x N/M Lower Multiple ABCL
Revenue Growth (YoY)
Growth
-76.3% -100.0% Higher Growth ABCL
Operating Margin (TTM)
Profitability
-1550.0% 0.0% Higher Margin RAPT
Net Profit Margin
Profitability
-248.8% 0.0% Higher Margin RAPT
Return on Equity (ROE)
Capital Efficiency
-17.3% -85.4% Higher ROE ABCL
52-Week Range Position
Momentum
68% ($3–$15) 100% ($1–$58) Stronger Trend RAPT
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol -0.02β · 2% Vol Lower Realized Risk RAPT
Unified Institutional Score
Composite Signal
63.3 / 100 (BUY) 52.4 / 100 (HOLD) Higher Composite ABCL
Trailing 12M Revenue (USD)
Operating Scale
$66M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 56.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$33M ($30M Net Cash) N/A ($9.02 Book/Sh · -85.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RAPT +1.72 pp
ABCL: -1.04% · RAPT: +0.68%
3M Horizon RAPT +69.49 pp
ABCL: +4.95% · RAPT: +74.44%
6M Horizon RAPT +98.43 pp
ABCL: +3.52% · RAPT: +101.95%
1Y Horizon RAPT +98.43 pp
ABCL: +3.52% · RAPT: +101.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABCL vs RAPT. Trailing 12-month operating profitability (ABCL -1550.0% vs RAPT 0.0%) and valuation multiples (ABCL 27.6x vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$66M
Gross MarginN/A
Op. Margin-1550.0%
ROE / Fwd P/E-17.3% · 27.6x
RAPT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABCL CONSOLIDATION
34d in phase · OBV NEUTRAL
Current IV 80.8%
IV Percentile 25th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RAPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABCL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8B market capitalization and -1550.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RAPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABCL vs RAPT Key Questions & Quantitative Answers

As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ABCL carries a Unified Composite Score of 63.3/100 (BUY) at $11.14 (27.6x Forward P/E, -1550.0% operating margin), whereas RAPT carries 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin). Technically, ABCL sits in a Neutral phase (RSI 43.3, CONSOLIDATION options structure) and RAPT sits in a Markup phase (RSI 79.7, UNCLASSIFIED options structure).

ABCL leads the Growth & Scale pillar: ABCL posts -76.3% YoY revenue growth and +45.9% YoY earnings growth on $66M TTM revenue (N/A gross margin, -1550.0% operating margin), compared with RAPT at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ABCL generates $66M in USD-normalized revenue versus N/A for RAPT. In operating R&D and SG&A reinvestment, ABCL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPT.

ABCL screens cheaper on headline valuation multiples. ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 56.9x EV/Revenue (-49.6% FCF margin), whereas RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABCL (-17.3% ROE) versus RAPT (-85.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ABCL carries 80.8% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.30β · 87% Vol realized risk). By comparison, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.